Any current/future new fundraising through debt or equity?

The company is undertaking significant CAPEX in FY25, peaking this year with Rs. 1,500 crore planned, primarily growth-led projects like Nitrotoluene, Ethylation, and Chlorotoluene value chain expansions. Current debt levels are around Rs. 3,300 crore, expected to peak between Rs. 3,500 to 3,800 crore during the year depending on raw material prices and working capital. Debt is likely to increase in the near term due to ongoing and planned CAPEX. There is no specific mention of equity fundraising in the provided transcript. The company plans to reduce CAPEX significantly after FY25, which shou

Any current/future capex/capital investment/strategic investment?

Rs. 400-500 crore CAPEX incurred for Ethylation capacity expansion, aiming for 3x increase to around 25,000 tons capacity. Nitrotoluene capacity being expanded from 30,000 tons to 45,000 tons (50% expansion). Bulk of ongoing CAPEX (~Rs. 1,500 crore for FY25) focused on commissioning of Ethylation, NCB, and pilot plant in Zone-IV related to Chlorotoluene value chain. Current FY25 CAPEX expected to peak; subsequent years to see significantly lower CAPEX. Strategic 50:50 Joint Venture with UPL (Augene Chemical Pvt Ltd) to manufacture downstream derivatives of amines for agrochemicals and paints,

Future growth expectations in sales/revenue/volumes?

Aarti Industries targets volume growth of 20% to 30% year-on-year for FY25, considered aspirational but achievable. Q1 FY25 saw over 30% volume growth YoY and a 6% QoQ increase. Positive demand momentum observed in key end-use applications: pharma, polymers, additives, dyes, pigments, and early signs of agrochemical recovery. Commissioning of new projects and better capacity utilization, especially in existing product chains, underpin the volume growth story. Growth anticipated to be volume-led despite margin pressures from Chinese competition. New capacity expansions: Nitrotoluene c

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth outlook remains robust, with expected volume growth of 20-30% driven by new project commissioning and better capacity utilization. QoQ volume growth was around 6%, with YoY volume growth above 30%. EBITDA showed a 10% QoQ increase and over 55% YoY growth; however, margin pressures from Chinese competition persist. Margins remain volatile, especially due to energy segment fluctuations linked to external factors like crude and naphtha cracks. No immediate margin recovery expected within 1-2 quarters; price recovery challenging due to China and global supply dynamics. ROCE expected

Aarti IndustriesQ1 FY25

Aarti Industries Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹460P/E: 32.3Market Cap: ₹16.9K Cr

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Aarti Industries targets volume growth of 20% to 30% year-on-year for FY25, considered aspirational but achievable.
Q1 FY25 saw over 30% volume growth YoY and a 6% QoQ increase.
Positive demand momentum observed in key end-use applications: pharma, polymers, additives, dyes, pigments, and early signs of agrochemical recovery.
Commissioning of new projects and better capacity utilization, especially in existing product chains, underpin the volume growth story.
Growth anticipated to be volume-led despite margin pressures from Chinese competition.
New capacity expansions: Nitrotoluene capacity increasing from 30,000 to ~45,000 tons; Ethylation capacity expected to triple from ~8,000-10,000 to ~25,000 tons.
The fuel additives business remains optimistic due to sustainable product demand despite the EV trend.
Longer-term growth aims also include expanding downstream specialty derivatives and new sunrise sectors like circularity and renewable battery chemistries.

Margin guidance

Category 3

Revenue growth outlook remains robust, with expected volume growth of 20-30% driven by new project commissioning and better capacity utilization.
QoQ volume growth was around 6%, with YoY volume growth above 30%.
EBITDA showed a 10% QoQ increase and over 55% YoY growth; however, margin pressures from Chinese competition persist.
Margins remain volatile, especially due to energy segment fluctuations linked to external factors like crude and naphtha cracks.
No immediate margin recovery expected within 1-2 quarters; price recovery challenging due to China and global supply dynamics.
ROCE expected to improve as new growth CAPEX peaks in FY25 and reduces in subsequent years.
Management cautious on full-year EBITDA guidance due to volatility but optimistic on sustained volume and long-term profitable growth.
Over the next decade, fuel additives demand remains optimistic despite EV trends due to sustained ICE engine presence and a shift to sustainable additives.

See what Aarti Industries management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company is undertaking significant CAPEX in FY25, peaking this year with Rs. 1,500 crore planned, primarily growth-led projects like Nitrotoluene, Ethylation, and Chlorotoluene value chain expansions.
Current debt levels are around Rs. 3,300 crore, expected to peak between Rs. 3,500 to 3,800 crore during the year depending on raw material prices and working capital.
Debt is likely to increase in the near term due to ongoing and planned CAPEX.
There is no specific mention of equity fundraising in the provided transcript.
The company plans to reduce CAPEX significantly after FY25, which should help contain or reduce debt levels going forward.

Order book

The transcript does not provide explicit details on the current or expected order book or pending orders for Aarti Industries Limited. However, related insights include: - The company is experiencing strong volume growth with a 6% QoQ and over 30% YoY increase in volumes. - New projects and better utilization of existing capacities are driving robust demand. - The recently formed JV with UPL is expected to begin commercial supplies by Q1 FY27 targeting Rs. 400-500 crore peak annual revenue over 2-3 years. - Long-term contracts announced (e.g., in energy segment) are on track to deliver volumes and margins as planned. - Overall, there is confidence in sustained volume growth of 20-30% for the fiscal year, driven by commissioned projects and improved capacity utilization. No direct figures or stated backlog/orderbook amounts are mentioned in the provided transcript.

See what Aarti Industries management said on order book — free account, 30 seconds.

Capex plans

Yes

Rs. 400-500 crore CAPEX incurred for Ethylation capacity expansion, aiming for 3x increase to around 25,000 tons capacity.
Nitrotoluene capacity being expanded from 30,000 tons to 45,000 tons (50% expansion).
Bulk of ongoing CAPEX (~Rs. 1,500 crore for FY25) focused on commissioning of Ethylation, NCB, and pilot plant in Zone-IV related to Chlorotoluene value chain.
Current FY25 CAPEX expected to peak; subsequent years to see significantly lower CAPEX.
Strategic 50:50 Joint Venture with UPL (Augene Chemical Pvt Ltd) to manufacture downstream derivatives of amines for agrochemicals and paints, enhancing product portfolio.
Focus on broadening product portfolio downstream and venturing into sunrise sectors like circularity, renewables, battery chemistries via R&D and technology investments.

Track Aarti Industries — get its next earnings analysis in your feed

How does Aarti Industries rank vs peers in ?

Pro feature

ThisAarti Industries

Rev 2Mar 3

See where Aarti Industries sits in See which companies these are, and every other name in the sector.Open rankings

What Aarti Industries's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →